Family · other
DSIP (Delta Sleep-Inducing Peptide)
Delta-sleep-inducing peptide; DSIP nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)
DSIP is a nonapeptide first isolated in 1977 from the blood of rabbits during electrically induced 'delta sleep,' initially proposed as an endogenous sleep-regulating factor. Decades of follow-up research have not established a clear, agreed mechanism of action; DSIP does not act through a single well-characterized receptor, and reviewers describe it as pleiotropic — reported (inconsistently) to interact with stress-hormone regulation (as a proposed corticotropin-releasing-factor modulator), circadian/temperature rhythms, and opioid- and GABA-related signalling in some animal studies. A 2006 review in the Journal of Neurochemistry explicitly frames DSIP as 'a still unresolved riddle,' noting that endogenous plasma DSIP-like immunoreactivity actually correlates with body temperature and is lower, not higher, during slow-wave and REM sleep — the opposite of what a simple 'sleep hormone' model would predict.
Human evidence is limited to a handful of small studies from the 1980s–1990s, mostly using intravenous synthetic DSIP in chronic insomniacs or healthy volunteers, with mixed and modest results (e.g., one small trial reported longer, less-interrupted sleep after IV DSIP in insomniac patients, with a brief arousing effect in the first hour before any sleep-promoting effect appeared). A separate controlled human study found that DSIP administration did not measurably affect CRH- and meal-induced ACTH/cortisol secretion, undercutting the proposed anti-stress mechanism. No modern, adequately powered, placebo-controlled human trials exist, DSIP is not established as an effective sleep aid, and its basic pharmacology (receptor, half-life, dose-response) remains poorly defined even in the specialist literature.
- Historical and ongoing basic research into endogenous sleep-regulatory and stress-axis signalling peptides
- Comparative pharmacology / peptide-signalling research (not an established sleep or anti-stress intervention)
Educational overview only — no dosing instructions in the public hub.
Because the mechanism and pharmacokinetics of DSIP remain poorly characterized even in the scientific literature, no reliable human safety profile exists. Claims that DSIP reliably improves sleep quality or reduces stress are not well supported by the available (old, small, mixed-result) human studies and should be treated with significant skepticism. Unregulated peptide sourcing adds contamination, mislabeling, and underfilling risk. Not evaluated by FDA/EMA/UK MHRA for any use.
Research samples should carry an independent third-party Certificate of Analysis confirming identity, purity (HPLC), and quantification by mass spectrometry (MS); unregulated vendors carry meaningful risk of mislabeled or underfilled vials.
Research Use Only (RUO) in most jurisdictions; not an approved drug or supplement in the EU, US, or UK. Sold, when available, strictly for laboratory/research use, not human consumption.
Frequently asked questions
- What is DSIP (Delta Sleep-Inducing Peptide) used for?
- Historical and ongoing basic research into endogenous sleep-regulatory and stress-axis signalling peptides. Comparative pharmacology / peptide-signalling research (not an established sleep or anti-stress intervention). Human evidence is limited to a handful of small studies from the 1980s–1990s, mostly using intravenous synthetic DSIP in chronic insomniacs or healthy volunteers, with mixed and modest results (e.g., one small trial reported longer, less-interrupted sleep after IV DSIP in insomniac patients, with a brief arousing effect in the first hour before any sleep-promoting effect appeared). A separate controlled human study found that DSIP administration did not measurably affect CRH- and meal-induced ACTH/cortisol secretion, undercutting the proposed anti-stress mechanism. No modern, adequately powered, placebo-controlled human trials exist, DSIP is not established as an effective sleep aid, and its basic pharmacology (receptor, half-life, dose-response) remains poorly defined even in the specialist literature.
- Is DSIP (Delta Sleep-Inducing Peptide) legal in Europe?
- Research Use Only (RUO) in most jurisdictions; not an approved drug or supplement in the EU, US, or UK. Sold, when available, strictly for laboratory/research use, not human consumption.
- What are the risks and side effects of DSIP (Delta Sleep-Inducing Peptide)?
- Because the mechanism and pharmacokinetics of DSIP remain poorly characterized even in the scientific literature, no reliable human safety profile exists. Claims that DSIP reliably improves sleep quality or reduces stress are not well supported by the available (old, small, mixed-result) human studies and should be treated with significant skepticism. Unregulated peptide sourcing adds contamination, mislabeling, and underfilling risk. Not evaluated by FDA/EMA/UK MHRA for any use.
- How is the quality of DSIP (Delta Sleep-Inducing Peptide) assessed?
- Research samples should carry an independent third-party Certificate of Analysis confirming identity, purity (HPLC), and quantification by mass spectrometry (MS); unregulated vendors carry meaningful risk of mislabeled or underfilled vials.